ImmuCell
Highly Engaged Employees
Highly Engaged EmployeesBlood & Organ Banks · Maine, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
56 Evergreen Dr, Portland, Maine, 04103,...Phone Number
(207) 878-2770Website
www.immucell.comRevenue
$29.9 MillionStock Symbol
ICCCIndustry
ZI Rank: 4
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
4
3
7
3
2
4
About ImmuCell
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics.Explore more
ImmuCell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ImmuCell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
ImmuCell, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on ImmuCell recently announced quarterly report
Check out if ImmuCell is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at ImmuCell
Funding: Get notified immidiatlly once ImmuCell has new funding data
Product Launch: Get notified when ImmuCell launches new products
Check if ImmuCell has recently received funding, and reach out quickly before it becomes old news!
Click to see if ImmuCell had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at ImmuCell
Find more new buyers
Compare Similar Companies to ImmuCell
Compare insights from companies similar to ImmuCell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ImmuCell is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
ImmuCell is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about ImmuCell.
ImmuCell financials insights
Gather financial insights about ImmuCell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Stock Offering
$5.9M
Share Placement
$3.5M
2017
Multiple Rounds
$10.3M
2019
Stock Offering
$8.3M
2020
Debt
$350K
2021
Share Placement
$4.3M
ImmuCell Tech Stack
A closer look at the technologies used by ImmuCell
Most Recent Scoops
Person-Based
Earnings, Sales, Finance
Earnings
ImmuCell has reported net income of $1.8 million, or $0.20 per share, for Q2 2026, compared to $500,000, or $0.06 per share, in Q2 2025, and net income of $3.8 million for the first six months of 2026, compared to $1.9 million during the same period in 2025, with both 2026 figures including the $2 million legal settlement received in Q2.
Earnings, Lawsuits, Legal Affairs, Settlement, Finance
Project
ImmuCell has launched initiatives to strengthen colostrum sourcing capabilities, including new payment programs, enhanced technical services, and expanded farm recruitment efforts, in response to increasing competition for high-quality colostrum, which represents approximately half of the company's product costs.
Spending/Investment, Recruitment, HR Operations
Earnings
ImmuCell has reported an increase in US market share for First Defense, defined as the share of animals treated with a biological scour preventative, from approximately 15% in December 2025 to approximately 19% at the end of June 2026, with the company's share of producer spending rising from approximately 29% to 38% over the same period.
Sales
Earnings
Earnings, Sales, Finance
ImmuCell News & Media
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call August 14, 2026 9:00 AM EDTCompany ParticipantsP. F.ImmuCell Q2 Earnings Call Highlights
ImmuCell (NASDAQ:ICCC) reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027. Product sales rose 11.5% year oveImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
Conference Call Scheduled for Friday, August 14, 2026 at 9:00 AM ET Conference Call Scheduled for Friday, August 14, 2026 at 9:00 AM ET
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ImmuCell
Sign Up For FreeTo access detailed company insights
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatmen... Read More
